Gardner Syndrome Treatment Global Market Report 2024

The gardner syndrome treatment market size has grown steadily in recent years. It will grow from $18.38 billion in 2023 to $19.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth observed during the historical period can be ascribed to progress in medical research, government regulations, the rising prevalence of Gardner syndrome, market competition, and improvements in healthcare infrastructure.

The gardner syndrome treatment market size is expected to see steady growth in the next few years. It will grow to $23.36 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The anticipated growth in the forecast period can be linked to advancements in treatment innovations, market trends, global economic factors, patient preferences, as well as pricing and reimbursement policies. Key trends expected in the forecast period encompass advancements in precision medicine, breakthroughs in immunotherapy, innovation in gene therapy, developments in diagnostic technologies, and collaborative research initiatives.

The anticipated increase in colon cancer cases is projected to drive the expansion of the market for Gardner syndrome treatment in the future. Colon cancer, originating in the large intestine, necessitates Gardner syndrome treatment to prevent cancer by removing polyps during a colonoscopy and employing chemotherapy. Notably, the American Society of Clinical Oncology (ASCO) reported in May 2022 that there were over 1.5 million colon cancer survivors in the USA, with expectations for this number to rise. The 5-year survival rate also witnessed a 65 percent increase, with 51,030 adults diagnosed with colon cancer in 2022, further fueling the growth of the Gardner syndrome treatment market.

The escalating trend of medical tourism is poised to contribute significantly to the advancement of the Gardner syndrome treatment market. Medical tourism involves individuals traveling to other countries for medical treatment, healthcare services, or surgical procedures. Destinations catering to medical tourism offer advanced Gardner syndrome treatment technologies and modalities. For instance, Travelperk, a Spain-based travel management company, reported in August 2023 that in 2021, 34,000 foreign visitors sought medical treatment in the UK. This surge in medical tourism is a key driver for the growth of the Gardner syndrome treatment market.

A noteworthy trend in gaining traction within the Gardner syndrome treatment market is product innovation. Leading companies in the market are focused on developing innovative solutions to strengthen their market position. For example, in December 2022, Genentech Inc., a US-based biotechnology corporation, introduced an innovative medicine named 'Lunsumio' (mosunetuzumab-axgb), approved by the U.S. Food and Drug Administration (FDA). This medicine, designed to treat adults with follicular lymphoma and rare diseases, stands out due to its intensive monitoring capabilities and its ability to provide T cells for enhanced defense against infections while effectively destroying cancer cells in the human body.

Major companies in the gardner syndrome treatment market are launching new products. In November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, unveiled Fruzaqla (fruquintinib), the first drug approved by the FDA for the treatment of metastatic colorectal cancer (mCRC) in adults. Fruzaqla targets all three subtypes of the vascular endothelial growth factor (VEGF) receptor kinases, making it a crucial treatment option, especially for patients with Gardner syndrome who are at a higher risk of developing colorectal cancer.

In February 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company, completed the acquisition of Amunix Pharmaceuticals Inc. for an undisclosed amount. This strategic move by Sanofi S.A. underscores its commitment to investing in promising research and discovery platforms, gaining access to Amunix's technologies, and accelerating the development of innovative medicines for oncology patients. Amunix Pharmaceuticals Inc., a US-based immuno-oncology and biopharmaceutical company, focuses on developing transformative therapies for oncology patients and manufacturing pharmaceutical products.

Major companies operating in the gardner syndrome treatment market report are Biochem Pharmaceuticals Industries Limited, Zydus Lifesciences Limited, Vernalis (R&D) Limited, Sun Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Mayne Pharma Group Limited, Akorn Operating Company LLC, Johnson & Johnson Private Limited, Medimetriks Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., GlaxoSmithKline plc, Novartis AG, Iris Pharma, Merck & Co. Inc., AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd.

North America was the largest region in the gardner syndrome treatment market in 2023. The regions covered in the gardner syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gardner syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary cancer types addressed in the treatment of Gardner syndrome include dilated cardiomyopathy, skeletal myopathy, neutropenia, and others. Dilated cardiomyopathy, a heart muscle disease that causes the chambers (ventricles) to thin and stretch, resulting in enlargement, is one of the key concerns. Therapeutic approaches encompass nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, applied in hospitals, specialty clinics, and various other settings.

The gardner syndrome treatment market research report is one of a series of new reports that provides gardner syndrome treatment market statistics, including gardner syndrome treatment industry global market size, regional shares, competitors with gardner syndrome treatment market share, detailed gardner syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the gardner syndrome treatment industry. This gardner syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.